Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Agranulocytosis D000380 7 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amnesia D000647 12 associated lipids
Anaphylaxis D000707 35 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Angina Pectoris D000787 27 associated lipids
Angina, Unstable D000789 14 associated lipids
Hypoxia D000860 23 associated lipids
Anthrax D000881 1 associated lipids
Arenaviridae Infections D001117 1 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthus Reaction D001183 8 associated lipids
Ascites D001201 25 associated lipids
Asphyxia Neonatorum D001238 4 associated lipids
Asthma D001249 52 associated lipids
Pulmonary Atelectasis D001261 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Birth Weight D001724 23 associated lipids
Blister D001768 16 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Body Weight D001835 333 associated lipids
Bovine Virus Diarrhea-Mucosal Disease D001912 2 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Brain Injuries D001930 4 associated lipids
Bronchial Diseases D001982 3 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchopulmonary Dysplasia D001997 4 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Burns D002056 34 associated lipids
Burns, Inhalation D002059 4 associated lipids
Carbon Monoxide Poisoning D002249 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Central Nervous System Diseases D002493 10 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cholecystitis D002764 8 associated lipids
Cholestasis D002779 23 associated lipids
Cholestasis, Intrahepatic D002780 4 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Hirt SW et al. Antagonisation of platelet activating factor--a new therapeutic concept for improvement of organ quality in lung preservation. 1992 Transpl. Int. pmid:14621825
Torras J et al. Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. 1993 Transpl. Int. pmid:8347271
Räisänen A et al. Effect of platelet-activating factor (PAF) receptor blockers on smooth muscle cell replication in vitro and allograft arteriosclerosis in vivo. 1993 Transpl. Int. pmid:8216700
Wang KS et al. Protective effects of a PAF antagonist against liver injury induced by warm ischemia or cold preservation. 1992 Transplant. Proc. pmid:1496669
Takada Y et al. Improvement of allograft viability with organs procured from non-heart-beating donors in porcine liver transplantation. 2000 Transplant. Proc. pmid:10715416
Fukuoka T et al. Platelet activating factor mediates systemic circulatory collapse after temporary hepatic inflow occlusion. 1993 Transplant. Proc. pmid:8470175
Peyman JA et al. HLA-DR genes are silenced in human trophoblasts and stimulation of signal transduction pathways does not circumvent interferon-gamma unresponsiveness. 1992 Transplant. Proc. pmid:1533073
Taniguchi S et al. Effects of a platelet-activating factor antagonist at different doses given simultaneously with double-filtration plasmapheresis on cardiac xenograft survival. 1994 Transplant. Proc. pmid:8171719
Coughlan AF et al. In vivo studies of P-selectin and platelet activating factor during endotoxemia, accelerated allograft rejection, and discordant xenograft rejection. 1993 Transplant. Proc. pmid:7692651
Hammer C et al. Xenogeneic rejection mechanisms shown by intravital microscopy. 1998 Transplant. Proc. pmid:9865335
Takada Y et al. Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. 1998 Transplant. Proc. pmid:9838621
Fukunaga K et al. Successful liver transplantation from non-heart-beating donors by blockade of endothelin and PAE. 1998 Transplant. Proc. pmid:9838664
Lloberas N et al. The ether phospholipids trail: blood timing in renal ischemia-reperfusion injury. 2002 Transplant. Proc. pmid:11959179
Castellvi J et al. Effect of the platelet-activating factor antagonist BN-52021 on liver preservation (4 degrees): experimental study in isolated reperfused rat liver model. 2002 Transplant. Proc. pmid:11959181
Metcalfe SM et al. Survival of renal allografted dogs after limited therapy with cyclosporine and the PAF antagonist WEB 2170. 1991 Transplant. Proc. pmid:1871852
Pirotzky E et al. Cyclosporine-induced nephrotoxicity: preventive effect of a PAF-acether antagonist, BN 52063. 1988 Transplant. Proc. pmid:3388505
Keskinoglu A et al. Inflammatory lipid mediators and immunologic recognition in allogeneic renal transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9122948
Otte KE et al. Xenoperfusion of rabbit kidney and the impact of BN 52021: a specific antagonist of platelet-activating factor. 1990 Transplant. Proc. pmid:2349668
Moreno P et al. Changes in peripheral blood levels of platelet-activating factor after orthotopic liver transplantation. 1993 Transplant. Proc. pmid:8395105
Kecskemeti V and Balogh I Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. 1995 Transplant. Proc. pmid:7482928
Yin M et al. Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. 1995 Transplant. Proc. pmid:7482939
Spiegel HU et al. Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. 1995 Transplant. Proc. pmid:7482955
Foegh ML Eicosanoids and platelet activating factor mechanisms in organ rejection. 1988 Transplant. Proc. pmid:3059615
Mahmoud FF et al. In vitro effects of ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5 expression in peripheral blood mononuclear cells from asthmatic subjects. 2002 Transplant. Proc. pmid:12431672
Borobia FG et al. Platelet-activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats. 1993 Transplant. Proc. pmid:8356661
Toledo-Pereyra LH and Suzuki S Cellular and biomolecular mechanisms of liver ischemia and reperfusion injury. 1994 Transplant. Proc. pmid:8109001
Iwamoto H et al. Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. 2000 Transplant. Proc. pmid:11119873
Da Costa M et al. Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170. 1990 Transplant. Proc. pmid:2389490
Bergmann R et al. Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys. 1990 Transplant. Proc. pmid:2389511
Immunomodulation: other approaches. 1988 Transplant. Proc. pmid:3347955
Renkonen R et al. Second messenger pathways in lymphocyte binding and penetration through graft vascular endothelium. 1991 Transplant. Proc. pmid:1846709
O'Hair DP et al. Platelet activating factor antagonist RP-59227 reduces vascular injury in discordant cardiac xenograft rejection. 1992 Transplant. Proc. pmid:1566490
Pignol B et al. Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection. 1988 Transplant. Proc. pmid:3259039
Miyatake T et al. Analysis of cardiac function during hyperacute rejection: effects of PAF antagonist, TXA(2) inhibitor/antagonists, and nitroglycerin. 2000 Transplant. Proc. pmid:10936319
First International Alexis Carrel Conference on Lipid Mediators in Organ Transplantation. April 8-10, 1986, Washington, DC. 1986 Transplant. Proc. pmid:3765055
Minor T et al. Treatment of preservation/reperfusion injury by platelet-activating factor antagonism in the rat liver graft. 1995 Transplant. Proc. pmid:7879086
Ide S et al. Donor administration of PAF antagonist (TCV-309) enhances lung preservation. 1995 Transplant. Proc. pmid:7879103
Takada Y et al. Platelet activating factor antagonist has a protective effect on preservation/reperfusion injury of the graft in pig liver transplantation. 1995 Transplant. Proc. pmid:7879169
Yin M et al. Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. 1995 Transplant. Proc. pmid:7879180
Pi F et al. Effect of a platelet-activating factor antagonist and desferrioxamine administration on eicosanoid production in rat pancreas transplantation. 1994 Transplantation pmid:8291097
Herrero-Fresneda I et al. Cold ischemia in the absence of alloreactivity induces chronic transplant nephropathy through a process mediated by the platelet-activating factor. 2000 Transplantation pmid:11190497
Gilli UO et al. Human polymorphonuclear neutrophils are recruited by porcine chemokines acting on CXC chemokine receptor 2, and platelet-activating factor. 2005 Transplantation pmid:15912099
Freiche JC et al. Prolonged survival of renal transplants in nonimmunized and hyperimmunized rats receiving a platelet-activating factor antagonist. 1990 Transplantation pmid:2368154
Makowka L et al. Platelet-activating factor and hyperacute rejection. The effect of a platelet-activating factor antagonist, SRI 63-441, on rejection of xenografts and allografts in sensitized hosts. 1990 Transplantation pmid:2402783
Biancone L et al. Platelet-activating factor synthesis and response on pancreatic islet endothelial cells: relevance for islet transplantation. 2006 Transplantation pmid:16495796
Biancone L et al. Role of platelet-activating factor in functional alterations induced by xenoreactive antibodies in porcine endothelial cells. 2000 Transplantation pmid:11063341
Yin M et al. The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. 1996 Transplantation pmid:8633367
Takada Y et al. Effects of platelet-activating factor antagonist on preservation/reperfusion injury of the graft in porcine orthotopic liver transplantation. 1995 Transplantation pmid:7839408
Conte JV et al. Long-term lung preservation with the PAF antagonist BN 52021. 1991 Transplantation pmid:2048190
Watson CJ et al. The platelet-activating factor antagonist WEB 2170. Its beneficial effect on dog renal allograft survival. 1993 Transplantation pmid:8212192